The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-month, double-blind, randomized, placebo-controlled trial
Diabetes Care, 04/06/2012Fraser DA et al.
The findings suggest that high–dose benfotiamine (300 mg/day) supplementation over 24 months has no significant effects upon peripheral nerve function or soluble markers of inflammation in patients with type 1 diabetes.
The study randomly assigned 67 patients with type 1 diabetes to receive 24–month benfotiamine (300 mg/day) or placebo supplementation.
Peripheral nerve function and levels of soluble inflammatory variables were assessed at baseline and at 24 months.
Fifty–nine patients completed the study.
Marked increases in whole–blood concentrations of thiamine and thiamine diphosphate were found in the benfotiamine group (both P < 0.001 vs. placebo).
However, no significant differences in changes in peripheral nerve function or soluble inflammatory biomarkers were observed between the groups.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.